CRDF Cardiff Oncology Inc

Price (delayed)

$2.69

Market cap

$116.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.9

Enterprise value

$98.58M

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to ...

Highlights
Cardiff Oncology's debt has decreased by 4.1% QoQ
The gross profit has increased by 6% QoQ but it has decreased by 2.8% YoY
Cardiff Oncology's revenue has increased by 6% from the previous quarter but it has decreased by 2.8% YoY
The net income has dropped by 64% year-on-year and by 11% since the previous quarter
Cardiff Oncology's EPS has shrunk by 55% YoY and by 8% QoQ

Key stats

What are the main financial stats of CRDF
Market
Shares outstanding
43.33M
Market cap
$116.57M
Enterprise value
$98.58M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.97
Price to sales (P/S)
303.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
256.72
Earnings
Revenue
$384,000
EBIT
-$37.79M
EBITDA
-$37.5M
Free cash flow
-$30.49M
Per share
EPS
-$0.9
Free cash flow per share
-$0.7
Book value per share
$2.78
Revenue per share
$0.01
TBVPS
$3.03
Balance sheet
Total assets
$131.26M
Total liabilities
$10.79M
Debt
$2.98M
Equity
$120.47M
Working capital
$118.93M
Liquidity
Debt to equity
0.02
Current ratio
15.02
Quick ratio
14.45
Net debt/EBITDA
0.48
Margins
EBITDA margin
-9,765.4%
Gross margin
100%
Net margin
-9,841.4%
Operating margin
-9,906.5%
Efficiency
Return on assets
-26.9%
Return on equity
-28.8%
Return on invested capital
-31.4%
Return on capital employed
-30.8%
Return on sales
-9,841.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRDF stock price

How has the Cardiff Oncology stock price performed over time
Intraday
-2.89%
1 week
-10.03%
1 month
-0.37%
1 year
-52.56%
YTD
-55.24%
QTD
22.27%

Financial performance

How have Cardiff Oncology's revenue and profit performed over time
Revenue
$384,000
Gross profit
$384,000
Operating income
-$38.04M
Net income
-$37.79M
Gross margin
100%
Net margin
-9,841.4%
Cardiff Oncology's net margin has shrunk by 69% YoY and by 4.2% QoQ
The operating margin has dropped by 69% year-on-year and by 3.7% since the previous quarter
The net income has dropped by 64% year-on-year and by 11% since the previous quarter
CRDF's operating income has dropped by 64% year-on-year and by 10% since the previous quarter

Growth

What is Cardiff Oncology's growth rate over time

Valuation

What is Cardiff Oncology stock price valuation
P/E
N/A
P/B
0.97
P/S
303.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
256.72
Cardiff Oncology's EPS has shrunk by 55% YoY and by 8% QoQ
The stock's price to book (P/B) is 61% less than its 5-year quarterly average of 2.5 and 25% less than its last 4 quarters average of 1.3
The equity has declined by 13% year-on-year and by 7% since the previous quarter
The P/S is 38% less than the last 4 quarters average of 490.5 and 2.6% less than the 5-year quarterly average of 311.4
Cardiff Oncology's revenue has increased by 6% from the previous quarter but it has decreased by 2.8% YoY

Efficiency

How efficient is Cardiff Oncology business performance
Cardiff Oncology's return on sales has shrunk by 69% YoY and by 4.2% QoQ
Cardiff Oncology's return on equity has decreased by 33% YoY and by 15% QoQ
CRDF's return on assets is down by 31% year-on-year and by 13% since the previous quarter
The company's return on invested capital rose by 19% YoY but it fell by 16% QoQ

Dividends

What is CRDF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRDF.

Financial health

How did Cardiff Oncology financials performed over time
The total liabilities has surged by 124% year-on-year and by 19% since the previous quarter
The company's current ratio has shrunk by 52% YoY and by 26% QoQ
Cardiff Oncology's debt is 98% lower than its equity
The equity has declined by 13% year-on-year and by 7% since the previous quarter
Cardiff Oncology's debt has decreased by 4.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.